Last checked at 5 Dec 2019 15:00
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
Director's Dealing
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that it has received notice that on 2 December 2019, Andrew Franklin, Chief Financial Officer of Alliance, exercised options over 1,500,000 new ordinary shares of 1 pence each in the Company ("Ordinary Shares") under the Company's Share Option Plans. The average exercise price was 46.75 pence.
Following this exercise, on 5 December 2019, Mr Franklin sold 1,371,616 Ordinary Shares at a price of 76.9 pence per share, and in accordance with the Group's share retention policy, retained 128,384 Ordinary Shares. Following these transactions, Mr Franklin's total beneficial interest in the Group is 128,384 Ordinary Shares, representing approximately 0.02 per cent. of the Group's issued share capital.
The 1,500,000 Ordinary Shares will be admitted to trading pursuant to an existing block listing, and will rank pari passu with the existing Ordinary Shares in issue.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||||
a) | Name | Andrew Franklin | |||||||
2 | Reason for the notification | ||||||||
a) | Position/status | Chief Financial Officer | |||||||
b) | Initial notification /Amendment | Initial Notification | |||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||
a) | Name | ALLIANCE PHARMA PLC | |||||||
b) | Legal Entity Identifier | 213800RYIWZA4Q5WPZ13 | |||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 1 pence each
GB0031030819 | |||||||
b) | Nature of the transaction | a) Exercise of options b) Sale of Ordinary Shares | |||||||
c) | Currency | GBP | |||||||
d) | Price(s) and volume(s) |
| |||||||
e) | Aggregated information - Aggregated volume - Price - Aggregated total | a) 1,500,000 options over Ordinary Shares, weighted average exercise price of 46.75 pence per Share. b) 1,371,616 Ordinary Shares, sold at a price of 76.9 pence per Ordinary Share, totalling £1,054,773.
| |||||||
f) | Date of the transaction | 2 December 2019 and 5 December 2019 | |||||||
g) | Place of the transaction | London Stock Exchange, AIM | |||||||
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah Ratcliff
Numis Securities Limited + 44 (0)20 7260 1000
Nominated Adviser: Freddie Barnfield, Huw Jeremy
Corporate Broking: James Black